Stevanato Group announced that they will exhibit Vertiva™, its On-Body delivery system platform for injectable therapies along with full primary packaging and device portfolio at PDA Universe and CPhI.

United States:  Stevanato Group S.p.A., a prominent global supplier of drug containment and delivery solutions for the pharmaceutical, biotechnology, and life sciences sectors, on October 16, 2023, announced the launch of its versatile on-body drug delivery platform, Vertiva™, at the PDA Universe and CPhI Barcelona events in the autumn. The live presentation of Vertiva™, at the PDA Universe and CPhI will presents a noteworthy occasion for Stevanato Group to demonstrate its dedication to advancing drug delivery technology and supporting pharmaceutical companies in delivering groundbreaking therapies to patients worldwide. Earlier this year in June 2023, Stevanato Group has introduced Vertiva™. This system is designed to facilitate the transition between basal and bolus injections and cater to a diverse range of subcutaneous therapies. Vertiva™ stands out with its distinctive configuration, comprising a disposable pod equipped with a pre-filled 3mL ISO cartridge and a reusable controller, potentially offering advantages in terms of sustainability and cost-effectiveness. These two components communicate through a patented magnetically coupled drive mechanism. The device can adapt to various delivery profiles and can administer both small-molecule drugs and biologics. The ongoing development of Vertiva™ includes expanding its design to accommodate a wide range of volumes, up to 10mL.

In the Vertiva™ device, the cartridge is preloaded and sealed within the pod during the manufacturing process, simplifying the initiation of treatment for patients. This design facilitates more convenient at-home administrations, and Vertiva™ offers connectivity options for potential use in digital health applications. After treatment, the separation of the pod and controller is made more straightforward, allowing for the controller's reuse, thus contributing to the reduced environmental impact of electronic components.

During the PDA Universe of Pre-filled Syringes and Injection Devices Conference, those who visit Stevanato Group's booth 69 will be granted an exclusive firsthand experience of the capabilities and potential of the Vertiva™ platform for drug delivery and the EZ-fill Smart™ ready-to-use vial platform for aseptic manufacturing.

Vertiva™ is fully customizable to deliver precise basal doses and complete bolus injections, making it suitable for an extensive array of therapies, including cardiovascular and metabolic disorders, oncology, immunology, and pain-related conditions. The Vertiva™ platform is adaptable to various customization options, encompassing primary packaging format for larger injection volumes, delivery duration, and user interface.

At the conference, the team from Stevanato Group will collaborate with experts from Bayer and Thermo Fisher Scientific to collectively provide valuable insights into their collaborative efforts to drive transformative innovation. These efforts are aimed at enhancing contract manufacturing services and expanding the portfolio of drug delivery devices to better support biopharmaceutical companies. As on March 2023, Stevanato Group collaborated with Thermo Fisher Scientific and last year on September 2022, they collaborated with Gerresheimer AG to bring to the market a fully integrated on-body delivery system platform.

Stevanato Group will be presenting its comprehensive range of products, technologies, and innovations in Drug Containment Systems and Drug Delivery Devices, which includes the Vertiva™ platform, at booth 2K20 during the CPhI exhibition. Attendees will have the chance to engage with the company's specialists and sales representatives to discover the extensive offerings tailored to biologics, encompassing GLP-1 obesity drugs, vaccines, diabetes, and mRNA solutions.